Equities research analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 4.8 %
Shares of EVOK opened at $5.38 on Tuesday. The firm has a market cap of $4.41 million, a PE ratio of -0.49 and a beta of 0.36. The company’s 50 day simple moving average is $5.04 and its 200-day simple moving average is $5.52. Evoke Pharma has a 12-month low of $3.54 and a 12-month high of $17.88.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The firm had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 514.74%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- How to buy stock: A step-by-step guide for beginners
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- Stock Average Calculator
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Pros And Cons Of Monthly Dividend Stocks
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
